Multiple Myeloma Clinical Trials
Cross-source consensus on Multiple Myeloma Clinical Trials from 1 sources and 5 claims.
1 sources · 5 claims
Where it comes from
Other
Other
Other
Highlighted claims
- The BLISS study population consists of participants enrolled in University of Leeds Clinical Trials Research Unit multiple myeloma trials from 2008 to 2021. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
- The included completed trials contain 5,517 participants. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
- BLISS will incorporate 10 clinical trials covering early-phase and late-phase studies in newly diagnosed and relapsed or refractory multiple myeloma. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
- Trial data extracted into BLISS will include demographics, treatment details, response assessments, progression outcomes, survival outcomes, and adverse events. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
- Participants are eligible for initial linkage if their first treating hospital was in England or if they later transferred to an NHS hospital in England during treatment. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data